As pharma continues to expand production for many in-demand biologics and vaccines, Avantor has announced plans to grow its capacity for single-use technologies.
Recently, the company reported that it will boost its manufacturing capacity for SUT by 30% at sites in the U.S. and EU. To meet its expansion goals, the company is increasing its SUT manufacturing footprint at facilities in North Carolina and in the Netherlands.
In addition, the company plans to double its current cleanroom space at a facility in Massachusetts.
Avanator says that the expansions will support pharma’s increased production of mAbs, cell and gene therapies, oncology treatments and COVID-19 vaccines.
"The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes,” Dr Ger Brophy, executive vice president of biopharma production at Avantor, said in a statement. "These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly.”
